Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Potential of extravasated platelet aggregation as a surrogate marker for overall survival in patients with advanced gastric cancer treated with preoperative docetaxel, cisplatin and S-1: a retrospective observational study

Fig. 3

Relapse-free survival curves for responders and non-responders in the p-DCS group and CD42b expression in the both groups. a: RECIST responders (P = 0.112; log-rank test). b: Histological responders (P = 0.004; log-rank test). c: CD42b expression in the p-DCS group (P = 0.013; log-rank test). d: CD42b expression in the control group (P = 0.015; log-rank test). DCS, docetaxel, cisplatin, and S-1; RECIST, Response Evaluation Criteria in Solid Tumors

Back to article page
\